Great Companies Deserve Great People Like You
Find your next career opportunity with one of the Midwest’s most exciting tech startups.
Locations
Columbus, OH, USA
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Series B
founded in
2016
Invirsa is developing a unique, broad platform based on a naturally occurring small molecule (INV-102) that has demonstrated enhanced immune response to infection. INV-102 not only reduces viral infection, and potentially bacterial replication, it also reduces inflammation, while enhancing the bodies wound healing response. Invirsa's technology is first being developed in the ophthalmology and pulmonary space. Invirsa’s technology has the potential to be a first line therapy for common infectious diseases, whether it's the 100 million viral pulmonary infections or the 5 million infectious conjunctivitis cases that occur every year in the US alone.
Something looks off?